PharmaCan Announces Corporate Rebranding to Become Cronos Group

Company News

PharmaCan Capital (TSXV: MJN) today announced a corporate rebranding to Cronos Group, to reflect the new strategic vision of the Company as Canada’s first bi-coastal licensed cannabis producer with interests in five Licensed Producers and three license applicants.

PharmaCan Capital (TSXV:MJN) today announced a corporate rebranding to Cronos Group, to reflect the new strategic vision of the Company as Canada’s first bi-coastal licensed cannabis producer with interests in five Licensed Producers and three license applicants.
As quoted in the press release:

“The rebranding was inspired by Greek mythology. As patron of the harvest, Cronos’ rule ushered in the ‘Golden Age’ and bountiful, healthy harvests. This new name allows us to emphasize our strategic vision of efficiently producing premium marijuana and distributing it across Canada and around the world,” said Cronos Group’s CEO, Mike Gorenstein.
The Company further announced two new additions to the Cronos Group. David Hsu has joined Cronos Group as Head of Operations. For over 10 years prior to joining Cronos Group, David successfully turned around and operated companies with revenues in excess of $500M. David’s expertise includes operational restructuring, lean manufacturing and growth creation. “David’s ability to efficiently manage capacity expansion and optimize large-scale production will accelerate Cronos Group’s emergence as a global leader in the cannabis industry,” said Gorenstein.
Cronos Group is also pleased to announce today that William Hilson has joined the company as Chief Financial Officer. Mr. Hilson is a Certified Public Accountant (CPA) and has spent over 15 years as regional CFO of two publicly listed multinational pharmaceutical companies — Merck KGaA and Serono S.A. His experience includes financial operations, strategy, performance management, sales & marketing, clinical trial management, international tax and debt & equity financing. Prior to joining Cronos Group, William was also involved in a number of mergers & acquisitions and licensing deals in the pharmaceutical sector.

 

The Conversation (0)
×